Cite
Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare
MLA
Timothy G. Call, et al. “Addition of Venetoclax at Time of Progression in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia: Combination Therapy to Prevent Ibrutinib Flare.” American Journal of HematologyREFERENCES, vol. 95, no. 3, Nov. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e311febaff680b596fa31d7a21ff2964&authtype=sso&custid=ns315887.
APA
Timothy G. Call, Neil E. Kay, Esteban Braggio, Eli Muchtar, Sameer A. Parikh, Susan M. Schwager, Thomas E. Witzig, Jose F. Leis, Kari G. Rabe, Daniel L. Van Dyke, Amie Fonder, Saad S. Kenderian, Wei Ding, Paul J. Hampel, Yucai Wang, Amber B. Koehler, & Susan L. Slager. (2019). Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. American Journal of HematologyREFERENCES, 95(3).
Chicago
Timothy G. Call, Neil E. Kay, Esteban Braggio, Eli Muchtar, Sameer A. Parikh, Susan M. Schwager, Thomas E. Witzig, et al. 2019. “Addition of Venetoclax at Time of Progression in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia: Combination Therapy to Prevent Ibrutinib Flare.” American Journal of HematologyREFERENCES 95 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e311febaff680b596fa31d7a21ff2964&authtype=sso&custid=ns315887.